Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Concord Drugs Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹76.75 |
|---|---|
| Day's Range | ₹74.00 - ₹78.35 |
| Open | ₹78.35 |
| 52 Week Range | ₹29.50 - ₹92.52 |
| Volume | 5,008 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3.84 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 94.97 |
| TTM EPS (₹) | 0.80 |
| P/E Ratio | 92.45 |
| Book Value(₹) | 2.07 |
| PAT Margin (%) | 0.74 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.19 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 79.69 | 369.46 |
| Expenses | N/A | N/A |
| PBT | 0.21 | 6.41 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 0.08 | 2.96 |
About Concord Drugs Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | S Nagi Reddy |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,48,147.79 | 1,871.70 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,009.45 | 6,742.45 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,779.35 | 4,491.00 | 3,154.10 - 3,154.10 |
| Apollo Hospitals Enterprise Ltd. | 1,22,039.38 | 8,573.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,772.31 | 1,437.35 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,932.40 | 1,096.00 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,08,616.36 | 1,327.25 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,07,749.13 | 2,371.55 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,04,915.68 | 1,081.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,04,477.66 | 2,470.80 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Jupiter Life Line Hospitals informs about AGM
Bal Pharma informs about closure of trading window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, Bal Pharma has informed that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st July 2026 and up to 48 hours of the declaration of the unaudited financial results of the Company for the quarter ended 30/06/2026. The date of the Board meeting for declaration of the unaudited financial results will be intimated to the exchange in due course.
The above information is a part of company’s filings submitted to BSE.
Aarti Pharmalabs informs about trading window closure
Sandu Pharmaceuticals informs about closure of trading window
Pursuant to the ‘Code of Conduct for Prevention of Insider Trading’ of the Company, SEBI (Prohibition of Insider Trading)Regulations, 2015 and clarification given by BSE vide its letter ref no LIST/COMP/01/2019-20 dated April 2,2019 regarding trading restrictions period, Sandu Pharmaceuticals has informed that the trading window for dealing in Securities of the Company shall remain closed from Wednesday, 01 July 2026 till 48 hours after the declaration of the financial results of the Company for the quarter ended 30th June 2026 for Directors, KMPs, Promoters And Promoters Group and Designated Persons ,Immediate Relative etc covered under the Code. The date of the Board Meeting for consideration of the Un Audited Financial Results of the Company for the Quarter ended 30th June 2026 will be intimated in due course. Accordingly, all Designated Persons and their immediate relatives are advised not to trade in the securities of the Company during the aforesaid trading window closure period.
Bacil Pharma informs about disclosure
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Concord Drugs Ltd. is ₹76.75 as of 2026-06-24.
The market capitalisation of Concord Drugs Ltd. is ₹100.20 as of 2026-06-23.
The 1-year return of Concord Drugs Ltd. is 47.23% as of 2025-06-23.
The P/E ratio of Concord Drugs Ltd. is 92.45 as of 2026-06-24.
The 52-week high and low of Concord Drugs Ltd. are ₹92.52 and ₹29.50, respectively, as of 2026-06-24.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
